Zealand Pharma — December 2021
-
Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome.
Interim analysis for the trial expected in third quarter of 2022
Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Company announcement – No. 76 / 2021 Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing...
GlobeNewswire News Room (www.globenewswire.com)
-
“We are delighted to reach this important milestone in the glepaglutide Phase 3 trial, which is the result of diligent work by our clinical research team and trial investigators, who have all labored to minimize the impact of Covid-19 on recruitment,” said Adam Steensberg, Chief Medical Officer at Zealand Pharma.
-
....
“We have experienced tremendous support and commitment from, and are incredibly grateful to, all of the patients, doctors, nurses, dieticians and other hospital staff involved in conducting this trial, in our joint efforts to develop a novel and convenient treatment option for patients with short bowel syndrome.”
-
Hele meddelelsen: Zealand Pharma - Company announcement - No. 76 / 202 https://www.proinvestor.com/index.php?p=debat_1&postid=99472
-
Hvad er det du ikke forstår i meddelelsen?
-
Ok..Det er noget helt andet end at forstå meddelelsen indhold på dansk.
-
Det er da fint nok at han gør det. Det er god service for nogen.
-
Det er er ikke en kurstrigger. Det er en blot opdatering på et igangværende forsøg.
-
Læs mere om forsøget på selskabets hjemmeside.
-
Tak for vidensdeling Helge og Exit. Det kan meget vel være tomgang indtil Q3, men spænding forude
-
Det var så lidt. At meddele til markedet, at den første og sidste patient er indrulleret til et forsøg er almindelig god praksis fra børsnoterede pharma- og biotekselskaber. Det fortæller at tingene kører som de skal.
-
og tak @Exitnu for, at bringe essensen af meddelelsen og ikke hele meddelelsen
-
Nogen kurstigger er det som nævnt normalt ikke.
-
Enig Helge. Det er ren ventetid nu. Tidshorisonten kan vi ikke ændre på.
-
Hvad er specielt kursdrivende i meddelelsen i din optik?
-
Den gode casen er efter mening uforandret udover at finansieringen er sikret. Hvordan kursen opfører sig på den helt korte bane er mindre interessant.
-
Der er kommet flere gode opdateringer fra Genmab på det seneste. Kursen ar faldet stort alligevel. Den slags er sket over en bred kam indenfor biotek de seneste måneder.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind